Alirocumab
Adding alirocumab to high-intensity statin therapy reduced high-risk plaques: PACMAN-AMI
WASHINGTON — In a new study, subcutaneous biweekly alirocumab, added to high-intensity statin therapy, resulted in greater coronary plaque regression in non-infarct-related arteries after 1 year in patients with acute MI.
Alirocumab does not impact AF risk after ACS
In patients with ACS, the PCSK9 inhibitor alirocumab did not impact the development of atrial fibrillation compared with placebo, according to new data from the ODYSSEY Outcomes trial.
In high-risk adults, consider combination therapy up front to achieve LDL goals
High-risk patients with clinical atherosclerotic cardiovascular disease or multiple CV risk factors benefit from more intensive lipid-lowering therapy, and clinicians should initiate combination treatment sooner, according to a speaker.
Many recent approvals, upcoming trials for lipid-lowering therapies
In an update on FDA approvals and late-breaking trials in lipid therapies, a speaker reviewed the current and future landscapes of LDL- and triglyceride-lowering therapies.
Economic value of alirocumab good if LDL greater than 100 mg/dL
In a cost-effectiveness model, the PCSK9 inhibitor alirocumab had good economic value at its present cost in patients with a baseline LDL greater than 100 mg/dL, though less value in patients with LDL less than 100 mg/dL.